Home » News » Nephrology » Secondary Hyperparathyroidism
Secondary Hyperparathyroidism
SECONDARY HYPERPARATHYROIDISM
The kidney stone rate appears to have risen among kidney transplant recipients over the past 2 decades, according to investigators.
Currently, there is no approved therapy for calciphylaxis.
Parathyroidectomy linked to reduced hazard of sustained decline in eGFR of at least 50% from baseline among those younger than 60 but not those aged 60 years and older
Study findings suggest strict PTH control might help preserve kidney graft function in children.
Further, baseline vitamin D-related biomarkers lower for individuals with higher BMI
Foot radiography and serum markers may be effective screening tools for early prevention and therapy.
The VITAL randomized clinical trial tested vitamin D and marine omega-3 fatty acid supplements in the primary prevention of cancer and cardiovascular disease.
Active vitamin D does not appear to improve bone strength or reduce fracture risk beyond PTH suppression in patients on dialysis.
On January 1, 2021, calcimimetics such as etelcalcetide were no longer reimbursed using the Transitional Drug Add-On Payment Adjustment.
Paricalcitol Independently Increases Hemoglobin Levels
Load More
Open
Next post in Secondary Hyperparathyroidism
Close
Close more info about Sodium Thiosulfate Does Not Improve Calciphylaxis in Chronic Kidney Disease
Loading...
Close more info about Sodium Thiosulfate Does Not Improve Calciphylaxis in Chronic Kidney Disease
Loading...